Programme. Announcement. 9th Prague Interdisciplinary Oncology Colloquium

Transcription

1 Under the auspices of: European Society for Medical Oncology (ESMO) Ministry of Health of the Czech Republic Ministry of Education, Youth and Sport of the Czech Republic Magistrate of the Capital City of Prague Czech Society for Oncology of the CzMA Neurooncological section of the Czech Oncological Society of the CzMA Society for Radiation Oncology, Biology and Physics of the CzMA Czech Gastroenterological Society of the CzMA Czech Hematology Society of the CzMA Czech Society of Internal Medicine of the CzMA Czech Pneumological and Phthisiological Society of the CzMA Czech Urological Society of the CzMA Czech Gynecological and Obstetrical Society CzMA Society of Gastrointestinal Oncology of the CzMA Czech Society for Palliative Medicine of the CzMA Charles University First Faculty of Medicine, Charles University Second Faculty of Medicine, Charles University Third Faculty of Medicine, Charles University Czech Association of Nurses General University Hospital in Prague Programme Announcement 9th Prague Interdisciplinary Oncology Colloquium Physicians and nurses of different disciplines together against malignant tumors World Interdisciplinary Oncology Colloquium January 24 26, 2018 Clarion Congress Hotel Prague **** Freyova 33, Prague 9, Czech Republic Host and organiser: We Make Media, s. r. o. / tel.: info@pragueonco.cz / Diamond Partner

2 Medical Section Programme Wednesday, 24 January to 3.15 p.m. Official opening 3.15 to 5 p.m. State of the Art Change in Treatment Paradigms in Oncology: From Personalized Medicine to Immunotherapy Christoph Zielinski (Austria) 5 to 5.15 p.m. Coffee break State of the Art in RCC Treatment Ignacio Duran (Spain) Access to Innovative Treatment in Europe Paul Cornes (Great Britain) Genomics in the Treatment of Lung Cancer New Perspective Nise Yamaguchi (Brazil) Liquid Biopsies in the Personalized Medicine Era Filip Janku (USA) 5.15 to 6.30 p.m. Highlights from the 2018 Gastrointestinal Cancers Symposium, San Francisco 6.30 to 7.45 p.m. Mini-colloquium: Treatment Schedules for Patients with mcrc Supported by Roche Thursday, 25 January to 8.15 a.m. Mini-colloquium: CABOMETYX - How Practical Experience Meets Data from Studies; What to Follow when Choosing Second-line Therapy in Patients with RCC Supported by IPSEN 8.30 to 10 a.m. Oncogynaecology Topic: The Most Frequent Mistakes in the Diagnostics and Treatment of Ovarian Cancer Diagnostics and Staging Daniela Fischerová Pathology Pavel Dundr First-line Therapy David Cibula 10 to a.m. Coffee break Treating Recurrent Diseases Lukáš Rob

3 10.30 to 12 a.m. Breast Cancers New Treatment Approach for Breast Cancers Peter Schmid (Great Britain) Personalized Medicine in Breast Cancer Funda Meric-Bernstam (USA) Endocrine Therapy Landscape Reshaped Metastatic Breast Cancer Elzbieta Senkus-Konefka (Poland) Metronomic Chemotherapy for Breast Cancer Marina Elena Cazzaniga (Italy) 12 a.m. to 1.15 p.m. Mini-colloquium: Progress in the Treatment of mcrc Supported by Servier 12 a.m p.m. Lunch 1.30 to 2.40 p.m. Colorectal Cancer 1.30 to 1.50 p.m. Genomically Driven Treatment of Localized and Metastatic Colorectal Cancer Marc Peeters (Belgium) 1.50 to 2.40 p.m. Panel discussion: 1.50 to 2 p.m. Adjuvant Therapy (case reports) Jiří Tomášek 2 to 2.10 p.m. Synchronous Metastases (case reports) Miroslav Ryska 2.10 to 2.40 p.m. Discussion 2.40 to 3.50 p.m. Stomach Cancer and Gastrooesophageal Junctions Surgery: 2.40 to 3 p.m. Surgery of Gastrooesophageal Junction Tumours - Double-cavity Operations. Current Situation and Prospects Robert Lischke 3 to 3.15 p.m. Surgery of Stomach Tumours Jaromír Šimša 3.15 to 3.25 p.m. The Status of Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Stomach and Gastrooesophageal Junction Cancer David Hoskovec, Zdeněk Krška Systemic Therapy: 3.25 to 3.30 p.m. Perioperative Chemotherapy: Why Yes Jindřich Fínek 3.30 to 3.35 p.m. Perioperative Chemotherapy: Why Not Luboš Petruželka 3.35 to 3.50 p.m. Panel discussion

4 4 to 5.15 p.m. Mini-colloquium: Who are the Targets for Targeted Therapy with Vectibix? Marc Peeters (Belgium), Supported by Amgen 5:30 to 6:30 p.m. Mini-colloquium: What 2017 Brought in Treatment of Colorectal Cancer and Prostate Cancer Supported by Sanofi Genzyme 6.30 to 7.30 p.m. 20th Anniversary from Establishing the Co-operative Group for Neuro-endocrine Tumours Supported by IPSEN Pharma Friday, 26 January to 8.25 a.m. Mini-colloquium: Approach to the Systemic Second-line Therapy of Advanced Adenocarcinomas of Stomach / Gastrooesophageal Junction Supported by Eli Lilly 8.30 to Genitourinary Tract Tumours Topic: Personalised Approach in the Diagnostics and Treatment of Prostate Cancer Moderators: Tomáš Hanuš, Luboš Petruželka Prostate Biopsy Using Digital Fusion of MRI and TRUS Pictures: an End of Saturation Biopsy? Otakar Čapoun Conventional Photon Beam vs. Short-range Radiotherapy: Negligible Toxicity? David Feltl Treatment of Localised Prostate Cancer from an Onco-urologist Perspective Ladislav Jarolím Personalised Approach to Hormonally Sensitive Prostate Cancer: Hormones Only? ARTA? Chemotherapy Directly? Luboš Petruželka Personalised Approach to Castrate-resistant Prostate Cancer: LATITUDE Study and others Roman Zachoval Discussion to a.m. Coffee break State of the Art The Treatment of Advanced Renal Cell Carcinoma Cezary Szczylik (Poland) to a.m. MUDr. Luboslava Krásná, PhD Award for the Best Poster to a.m. Mini-colloquium: New Perspectives in the Treatment of Patients with Advanced Follicular Lymphoma Supported by Roche 11 to a.m. Lung Cancer Immunotherapy in Lung Cancer Treatment Nir Peled (Israel)

5 12.45 to 2 p.m. Lunch Lung Cancer Radiotherapy: update Milada Zemanová Developments in Adjuvant Therapy of NSCLC Vítězslav Kolek Developments in the Treatment of Small-cell Lung Cancer Luboš Petruželka Developments in the Treatment of Squamous Cell Cancer Miloš Pešek Biomarkers and Predictive Markers in Pneumo-oncology, Liquid Biopsy Kristýna Němejcová Endoscopic Diagnostics of Solitary Lung Nodes and the Need for Re-biopsy in Pneumo-oncology Jiří Votruba Developments in the Treatment of ALK-positive & NSCLC Libor Havel to 2 p.m. Mini-colloquium: Inotuzumab ozogamicin - a New Option for Patients with Relapsed/Refractory ALL Supported by Pfizer to 2 p.m. Mini-colloquium: Pembrolizumab - Give Your Patients the Key to Surviving Better Supported by MSD 2 to 3.30 p.m. Haemato-oncology: Lymphomas in Patients of Advanced Age Epidemiology of Lymphomas in Advanced Age Marek Trněný 3.30 to 3.45 p.m. Coffee break The Importance of Maintenance Therapy with Rituximab in Patients with Follicular Lymphomas David Belada Elderly Patients with Peripheral T Lymphomas Andrea Janíková Mantle Cell Lymphomas in Elderly Patients Pavel Klener Attitude to Elderly Patients with Hodgkin Lymphoma Alice Sýkorová Treatment of Patients with Diffuse Large B-cell Lymphomas Vít Procházka, Tomáš Fürst, Tomáš Papajík Haematopoietic Stem Cell Transplantation in Elderly Patients with Lymphomas Robert Pytlík

6 3.45 to 4.55 p.m. Prevention in Oncology 15 Years of the Breast Cancer Screening Programme in the Czech Republic Jan Daneš 4.55 to 5 p.m. Official closing Prevention of Malignant Diseases in Consulting Rooms of General Practitioners Norbert Král Physical Activity in the Prevention of Malignant Diseases Martin Matoulek Genetic Advisory and Monitoring Healthy Carriers of High-risk Mutations Monika Koudová Oncological Treatment and Smoking Eva Králíková